Caris Life Sciences Inc.

06/05/2026 | Press release | Distributed by Public on 06/05/2026 15:04

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.
Caris Life Sciences, Inc. (the "Company") held its 2026 Annual Meeting of Shareholders on June 4, 2026 (the "2026 Annual Meeting"). The Company's shareholders were asked to vote on two proposals, each as more fully described in the Company's Definitive Proxy Statement filed with the Securities and Exchange Commission on April 23, 2026: (1) to elect ten director nominees to the Board to serve until the 2027 Annual Meeting of Shareholders and until their respective successors are duly elected and qualified or their earlier death, resignation, disqualification or removal; and (2) to ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
As of the close of business on the record date of April 9, 2026, there were 282,662,545 shares of the Company's common stock issued, outstanding and eligible to vote if represented in person or by proxy at the 2026 Annual Meeting. A total of 273,714,520 shares were represented at the 2026 Annual Meeting, which constituted a quorum.
The shareholder voting results by proposal are set forth in the tables below:
Proposal No. 1: Election of Directors
Each of the following director nominees was elected to serve for a term expiring at the 2027 Annual Meeting by the votes set forth in the table below.
Name Votes For Votes Withheld Broker Non-Votes
David Dean Halbert 216,983,424 45,644,070 11,087,026
Brian J. Brille 216,953,607 45,673,887 11,087,026
Peter M. Castleman 200,435,909 62,191,585 11,087,026
David Fredrickson 228,579,061 34,048,433 11,087,026
Joseph E. Gilliam 215,798,279 46,829,215 11,087,026
Jon S. Halbert 215,600,787 47,026,707 11,087,026
Laura I. Johansen 227,201,421 35,426,073 11,087,026
Dr. Lloyd B. Minor 228,662,425 33,965,069 11,087,026
Danny Phillips 214,817,153 47,810,341 11,087,026
Dr. Jeffrey Vacirca 228,673,484 33,954,010 11,087,026
Proposal No. 2: Ratification of Appointment of Independent Registered Public Accounting Firm
The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified by the shareholders by the votes set forth in the table below.
Votes For Votes Against Abstentions
273,517,324 60,882 136,314
Caris Life Sciences Inc. published this content on June 05, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT) on June 05, 2026 at 21:04 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]